Search | Clinical Trials Finder

Conditions: Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis, MF
Interventions: Navtemadlin, Navtemadlin placebo, Ruxolitinib; Drug
Lead sponsor: Kartos Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 58
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 52 more

Conditions: Myelofibrosis (MF)
Interventions: Mivebresib, Navitoclax, Ruxolitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Stony Brook, New York • Cincinnati, Ohio • Knoxville, Tennessee + 1 more

Conditions: MPN (Myeloproliferative Neoplasms)
Interventions: Not listed
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 114
States / cities: Huntsville, Alabama • Tempe, Arizona • Tucson, Arizona + 111 more

Conditions: Myelodysplastic Syndrome (MDS), Myelofibrosis (MF)
Interventions: KB004, Monoclonal Antibody; Drug
Lead sponsor: Humanigen, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 7
States / cities: Palo Alto, California • Sacramento, California • Miami, Florida + 4 more

Conditions: Cutaneous T-Cell Lymphomas
Interventions: TSEBT, TSEBT and pembrolizumab; Radiation · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Myelofibrosis (MF)
Interventions: Navitoclax, Ruxolitinib, Best Available Therapy (BAT); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 41
States / cities: Chandler, Arizona • Springdale, Arkansas • Duarte, California + 34 more

Conditions: Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Interventions: Glasdegib (PF-04449913), Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 15
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 6 more

Conditions: Myeloproliferative Disorders
Interventions: SB939; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cutaneous T Cell Lymphoma, Mycosis Fungoides
Interventions: Mogamulizumab, Brentuximab vedotin; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Interventions: Hypericin, Mechlorethamine Topical Gel; Drug
Lead sponsor: Soligenix; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Fairport, New York

Conditions: Myelofibrosis
Interventions: Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg; Drug
Lead sponsor: Geron Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 29
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 26 more

Conditions: Cystic Fibrosis
Interventions: VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA, Placebo (matched to VX-121/TEZ/D-IVA), Placebo (matched to ELX/TEZ/IVA), Placebo (matched to IVA); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 69
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 61 more

Conditions: Healthy
Interventions: MF101; Drug
Lead sponsor: Bionovo; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Chronic Rhinosinusitis (CRS), Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Interventions: OCEAN, Steroid-eluting sinus stent; Device
Lead sponsor: Polyganics BV; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Colorado Springs, Colorado • Atlanta, Georgia • Chicago, Illinois + 6 more

Conditions: Cataract
Interventions: Tecnis MF, ReSTOR; Device
Lead sponsor: Innovative Medical; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Miami, Florida • Sarasota, Florida

Conditions: Myeloproliferative Neoplasm
Interventions: Navitoclax, Ruxolitinib, Celecoxib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 12
States / cities: Duarte, California • Fullerton, California • La Jolla, California + 9 more

Conditions: Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Interventions: Cobomarsen, Vorinostat; Drug
Lead sponsor: miRagen Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 16 more

Conditions: Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Myelodysplastic Syndromes
Interventions: DISC-0974; Drug
Lead sponsor: Disc Medicine, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 26
States / cities: Gilbert, Arizona • Duarte, California • Irvine, California + 21 more

Conditions: Cutaneous T-cell Lymphoma, Cutaneous T-cell Lymphoma Stage I, Mycosis Fungoides, Folliculotropic Mycosis Fungoides, Granulomatous Slack Skin, Syringotropic Mycosis Fungoides, Mycosis Fungoides Variant, Transformed Mycosis Fungoides
Interventions: Triamcinolone, Valchlor 0.016 % Topical Gel; Drug
Lead sponsor: Rochester Skin Lymphoma Medical Group, PLLC; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Fairport, New York

Conditions: Mycosis Fungoides
Interventions: Mogamulizumab-Kpkc, Phototherapy; Drug · Device
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Mycosis Fungoides
Interventions: Valchlor; Drug
Lead sponsor: Helsinn Therapeutics (U.S.), Inc; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 36
States / cities: Little Rock, Arkansas • Duarte, California • La Mesa, California + 28 more

Conditions: Myelofibrosis (MF)
Interventions: Placebo for Navitoclax, Ruxolitinib, Navitoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 35
States / cities: Springdale, Arkansas • Fullerton, California • La Jolla, California + 29 more

Conditions: Myelofibrosis (MF)
Interventions: Ruxolitinib, Navitoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 33
States / cities: Birmingham, Alabama • Cerritos, California • Duarte, California + 27 more

Conditions: Myelofibrosis, Polycythemia Vera, Thrombocythemia
Interventions: itacitinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: New Orleans, Louisiana • Bethesda, Maryland • Kansas City, Missouri + 5 more

Search by objective public record fields.

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)

Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Study of SB939 in Subjects With Myelofibrosis

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Phase I Study to Evaluate the Safety and Efficacy of MF101 as Well as the Pharmacokinetics of Its Key Active Components

Evaluation of the Safety and Performance of a Bioresorbable Nasal Dressing Containing Mometasone Furoate (MF)

Evaluation Of Bilateral Tecnis Multifocal Versus ReSTOR 3D Intraocular Lenses

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Mechlorethamine Induced Contact Dermatitis Avoidance Study

Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)

Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)